Trial Profile
Phase II, multicenter, open-label, single-arm trial in advanced and relapsed Angiosarcomas, to evaluate the efficacy of pazopanib (Votrient) in combination with standard of care treatment paclitaxel ( Evaluation of Votrient in angiosarcoma - EVA)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Paclitaxel
- Indications Haemangiosarcoma; Tumours
- Focus Therapeutic Use
- Acronyms EVA
- 23 Jan 2020 This trial has been discontinued in Germany, according to European Clinical Trials Database record. (global end of the trial: 2019-12-31)
- 29 Jul 2014 New trial record